ReviewMetabolomics : Official journal of the Metabolomic Society2026
Outcomes and future activities of the 'Pan-European network in Lipidomics and EpiLipidomics - EpiLipidNET'.
Review in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipidomics and its branch epilipidomics are rapidly advancing fields that explore the roles of native and modified lipids (e.g., oxidized, nitrated and halogenated lipid species), respectively, in biological systems. Dysregulation of lipid metabolism and signaling contributes to numerous diseases, including cardiovascular, metabolic, neurodegenerative, and inflammatory conditions. However, multiple challenges, including lack of standardization, limited data integration, and poor clinical translation, hinder progress. To address these, the COST Action EpiLipidNET (CA19105) established a pan-European network fostering collaboration across disciplines to accelerate lipid science and its application to health and disease. AIM OF REVIEW: This review outlines the achievements of EpiLipidNET over its four-year duration, highlights key scientific contributions across five thematic working groups, and presents the future direction of its ongoing activities. The aim is to demonstrate how a collaborative, interdisciplinary framework can catalyze innovation in lipidomics and epilipidomics, enhance methodological harmonization, support early-career researchers, and bridge the gap between basic science, clinical translation, industry, stakeholders, and public engagement. KEY SCIENTIFIC CONCEPTS OF REVIEW: EpiLipidNET structured its networking activities around (i) harmonization of analytical workflows, (ii) development of epilipidomics tools and data integration strategies, (iii) translational studies for clinical lipid biomarkers, (iv) investigation of lipid signaling mechanisms, and (v) dissemination and outreach. The network supported over 460 members globally, launched multiple training schools and scientific missions, produced 110+ publications, and fostered new initiatives in endothelial membrane lipidomics, food lipidomics, plant and algae lipids, and redox lipid biology. Its integrative approach sets a foundation for continued progress toward precision medicine and sustainable health interventions through lipid science.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.